The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes

Diabetes Care

Volumn 27, Issue 7, 2004, Pages 1688-1691

  Rubio Guerra, Alberto Francisco ^a,b   Arceo Navarro, Adalberto ^b   Vargas Ayala, German ^a,b   Rodriguez Lopez, Leticia ^a,b   Lozano Nuevo, Jose Juan ^a,b   Gomez Harper, Carlos Treñro ^a  

^a Hospital General de Ticoman SS DF   (Mexico)

^b Ticoman Grp for Hypertension Res   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; URINARY EXCRETION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; HEART RATE; HUMANS; INDOLES; INFANT, NEWBORN; MALE; MIDDLE AGED; PROTEINURIA; REFERENCE VALUES; VERAPAMIL;

EID: 3042789263     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.7.1688     Document Type: Article

References (14)

1. Kraig KJ, Owens DR, Donovan K, Williams J, Munnery M, Phillips AO: Identification and management of diabetic nephropathy in the diabetes clinic. Diabetes Care 26:1806-1811, 2003
2. Tomlinson JW, Owen KR, Close CF: Treating hypertension in diabetic nephropathy. Diabetes Care 26:1802-1805, 2003
3. Velazquez O, Rosas M, Lara A, Pastelin G, Castillo C, Attie F, Tapia R: Prevalencia e interrelación de enfermedades crónicas no transmisibles y factores de riesgo cardiovascular en Mexico. Arch Cardiol Mex 73:62-77, 2003
4. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011-1053, 2003
5. Sasso FC, Carbonara O, Persico M, Iafusco D, Salvatore T, D'Ambrosio R, Torella R, Cozzolino D: Irbesartan reduces the excretion rate in mycroalbuminuric type 2 diabetes Independently of hypertension. Diabetes Care 25:1909-1913, 2002
6. Kaplan NM: Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence. Ann Intern Med 135:1079-1083, 2001
7. Rubio AF, Treviño CJ, Vargas G, Lozano JJ, Rodríguez L, Arceo A: Renoprotective effects of the combination trandolapril/verapamil in patients with type 2 diabetes mellitus and hypertension. Clin Drug Invest 22:541-546, 2002
8. Bakris G, Weir MR, DeQuatro V, McMahon FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 54:1283-1289, 1998
9. Molitch ME: Management of early diabetic nephropathy. Am J Med 102:392-398, 1997
10. Rabelink TJ, Koomans HA: Endothelial function and the kidney. Drugs 53:11-19, 1997
11. Park JK, Fiebeler A, Muller DN, Mervaala EM, Dechend R, Abou-Rebyeh F, Luft FC, Haller H: Lacidipine inhibits adhesion molecule and oxidase expression independent of blood pressure reduction in angiotensin-induced vascular injury. Hypertension 39:68-689, 2002
12. Steffes MW: Diabetic nephropathy: incidence, prevalence, and treatment. Diabetes Care 20:997-998, 1997
13. Fernández R, Puig JC, Rodríguez JC, Garrido J, Redon J: Effect of two antihypertensive combinations on metabolic control in type 2 diabetic hypertensive patients with albuminuria: a randomized double-blind study. J Hum Hypertens 15: 849-856, 2001
14. Berlowitz DR, Ash A, Hickey E, Glickman M, Friedman R, Kader B: Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care 26:355-359, 2003